Amneal Pharmaceuticals, Inc.
AMRX
$12.60
-$0.18-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 722.52M | 814.32M | 784.51M | 724.51M | 695.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 722.52M | 814.32M | 784.51M | 724.51M | 695.42M |
| Cost of Revenue | 403.95M | 518.54M | 490.19M | 440.27M | 441.30M |
| Gross Profit | 318.57M | 295.78M | 294.32M | 284.24M | 254.12M |
| SG&A Expenses | 138.86M | 146.48M | 137.82M | 124.27M | 118.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -64.00K | -1.00K | -117.00K | -- | -5.12M |
| Total Operating Expenses | 581.13M | 699.82M | 691.24M | 612.50M | 594.50M |
| Operating Income | 141.39M | 114.50M | 93.27M | 112.01M | 100.92M |
| Income Before Tax | 80.18M | 55.24M | -5.22M | 51.71M | 37.49M |
| Income Tax Expenses | 2.18M | 5.66M | -23.36M | 16.10M | 12.87M |
| Earnings from Continuing Operations | 78.00M | 49.57M | 18.13M | 35.61M | 24.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.74M | -14.50M | -15.76M | -13.19M | -12.42M |
| Net Income | 62.26M | 35.08M | 2.37M | 22.42M | 12.20M |
| EBIT | 141.39M | 114.50M | 93.27M | 112.01M | 100.92M |
| EBITDA | 184.58M | 163.73M | 147.34M | 172.12M | 161.08M |
| EPS Basic | 0.20 | 0.11 | 0.01 | 0.07 | 0.04 |
| Normalized Basic EPS | 0.11 | 0.07 | 0.05 | 0.06 | 0.04 |
| EPS Diluted | 0.19 | 0.11 | 0.01 | 0.07 | 0.04 |
| Normalized Diluted EPS | 0.11 | 0.07 | 0.05 | 0.06 | 0.04 |
| Average Basic Shares Outstanding | 316.02M | 314.46M | 314.17M | 313.74M | 311.05M |
| Average Diluted Shares Outstanding | 328.93M | 328.09M | 324.75M | 322.36M | 323.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |